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Separate and combined associations of body-mass index and 
abdominal adiposity with cardiovascular disease: 
collaborative analysis of 58 prospective studies
The Emerging Risk Factors Collaboration*
Summary
Background Guidelines diﬀ er about the value of assessment of adiposity measures for cardiovascular disease risk 
prediction when information is available for other risk factors. We studied the separate and combined associations of 
body-mass index (BMI), waist circumference, and waist-to-hip ratio with risk of ﬁ rst-onset cardiovascular disease.
Methods We used individual records from 58 cohorts to calculate hazard ratios (HRs) per 1 SD higher baseline values 
(4·56 kg/m² higher BMI, 12·6 cm higher waist circumference, and 0·083 higher waist-to-hip ratio) and measures of 
risk discrimination and reclassiﬁ cation. Serial adiposity assessments were used to calculate regression dilution ratios.
Results Individual records were available for 221 934 people in 17 countries (14 297 incident cardiovascular disease 
outcomes; 1·87 million person-years at risk). Serial adiposity assessments were made in up to 63 821 people (mean 
interval 5·7 years [SD 3·9]). In people with BMI of 20 kg/m² or higher, HRs for cardiovascular disease were 1·23 
(95% CI 1·17–1·29) with BMI, 1·27 (1·20–1·33) with waist circumference, and 1·25 (1·19–1·31) with waist-to-hip 
ratio, after adjustment for age, sex, and smoking status. After further adjustment for baseline systolic blood pressure, 
history of diabetes, and total and HDL cholesterol, corresponding HRs were 1·07 (1·03–1·11) with BMI, 1·10 (1·05–1·14) 
with waist circumference, and 1·12 (1·08–1·15) with waist-to-hip ratio. Addition of information on BMI, waist 
circumference, or waist-to-hip ratio to a cardiovascular disease risk prediction model containing conventional risk 
factors did not importantly improve risk discrimination (C-index changes of –0·0001, –0·0001, and 0·0008, 
respectively), nor classiﬁ cation of participants to categories of predicted 10-year risk (net reclassiﬁ cation improvement 
–0·19%, –0·05%, and –0·05%, respectively). Findings were similar when adiposity measures were considered in 
combination. Reproducibility was greater for BMI (regression dilution ratio 0·95, 95% CI 0·93–0·97) than for waist 
circumference (0·86, 0·83–0·89) or waist-to-hip ratio (0·63, 0·57–0·70).
Interpretation BMI, waist circumference, and waist-to-hip ratio, whether assessed singly or in combination, do not 
importantly improve cardiovascular disease risk prediction in people in developed countries when additional 
information is available for systolic blood pressure, history of diabetes, and lipids.
Funding British Heart Foundation and UK Medical Research Council.
Introduction
National and international guidelines have provided 
diﬀ ering recommendations about the value of clinical 
measures of adiposity for prediction of cardiovascular 
disease risk in primary prevention.1 Recommendations 
range from omission of adiposity measures, to inclusion 
of such measures as additional screening tests, to formal 
inclusion of such measures as risk factors in prediction 
models. For example, whereas WHO2 and the US 
National Heart, Lung and Blood Institute3 recommend 
assessment of both body-mass index (BMI) and waist 
circumference in people with a BMI of 25·0–34·9 kg/m², 
several often used cardiovascular disease risk scores omit 
adiposity measures (eg, Framingham, SCORE, PROCAM, 
Reynolds), but others include BMI (eg, QRISK).4
This divergence in guideline recommendations might, 
in part, indicate uncertainties in relation to data from 
previous studies. For example, in a large multinational 
retrospective case-control study, waist-to-hip ratio was 
three times more strongly related to risk of acute 
myocardial infarction than was BMI.5 However, these 
suggestions have not been tested by powerful prospective 
studies with assessment of BMI, waist circumference, and 
waist-to-hip ratio in the same people.6–12 Prospective 
studies of adiposity have often lacked concomitant 
measurement of lipids and other conventional risk factors, 
which has impeded assessment of adiposity measures in 
the context of standard risk prediction scores.8,13 
Furthermore, because studies have often reported on 
measures of association (such as relative risks) rather than 
on speciﬁ c measures of predictive ability (eg, measures of 
risk discrimination and reclassiﬁ cation), they might not 
have been able to make an optimum assessment of 
predictive ability (as opposed to aetiological importance).14,15 
Finally, reliable comparison of the long-term reproduci-
bility of BMI, waist circumference, and waist-to-hip ratio 
has been lacking.
The objective of this report was to analyse individual 
data from 221 934 participants in 58 prospective studies 
to produce reliable estimates of associations of BMI, 
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waist circumference, and waist-to-hip ratio with ﬁ rst-
onset cardiovascular disease outcomes. We quantiﬁ ed 
the incremental gain in cardiovascular disease prediction 
with these adiposity measures, singly and in combin-
ation, under a wide range of circumstances. We also 
compared the reproducibility of adiposity measures by 
use of serial measurements taken over several years in 
up to 63 821 people.
Methods
Study design
Details of the Emerging Risk Factors Collaboration have 
been described previously.16–19 This analysis involved 
individual records from 58 prospective studies with the 
following four features (webappendix pp 12 and 27–30): 
(1) participants were not selected on the basis of having 
previous vascular disease; (2) concomitant information 
was provided at baseline for weight, height, and waist 
and hip circumference; (3) cause-speciﬁ c mortality or 
vascular morbidity, or both, were recorded by use of 
well deﬁ ned criteria; and (4) at least 1 year of follow-up 
had been accrued. In registration of fatal outcomes, all 
contributing studies used codings from the International 
Classiﬁ cation of Diseases to at least three digits (or 
used study-speciﬁ c classiﬁ cation systems), and ascer-
tainment was based on death certiﬁ cates. 43 of the 
58 contributing studies also used medical records, 
autopsy ﬁ ndings, and other supplementary sources to 
help classify deaths. 50 studies used deﬁ nitions of 
myocardial infarction based on WHO criteria. 43 studies 
reported diagnosis of strokes on the basis of brain 
imaging, and attributed stroke subtype.
This study was approved by the Cambridgeshire ethics 
review committee.
Statistical analysis
We assessed BMI, waist circumference, and waist-to-hip 
ratio in relation to three fatal or ﬁ rst-ever non-fatal 
Figure 1: HRs for coronary heart disease and ischaemic stroke across quantiles of baseline BMI, waist circumference, and waist-to-hip ratio
Regression analyses were stratiﬁ ed, where appropriate, by sex. Adjusted study-speciﬁ c log HRs were combined by multivariate random-eﬀ ects meta-analysis. Y-axes 
are shown on a log scale. Reference groups are the second deciles in the plots for coronary heart disease and the ﬁ rst quintiles in the plots for ischaemic stroke. 
HR=hazard ratio. BMI=body-mass index. *Intermediate risk factors were systolic blood pressure, history of diabetes, and total and HDL cholesterol.
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outcomes: coronary heart disease; ischaemic stroke; and 
coronary heart disease and any cerebrovascular disease 
(ie, cardiovascular disease). Because waist-to-height ratio 
was highly correlated with waist circumference (r=0·95, 
95% CI 0·94–0·96), waist-to-height ratio was not reported 
separately. Analyses were done in two stages by use of 
estimates of association calculated separately within each 
study before pooling across studies by random-eﬀ ects 
meta-analysis.20 Hazard ratios (HRs) were calculated with 
Cox proportional hazard regression models, stratiﬁ ed by 
sex, with censoring of deaths from non-cardiovascular 
disease causes. The proportional hazards assumptions 
were met. To avoid overﬁ tting of the statistical models, 
studies with fewer than ten incident cases of an outcome 
were excluded from analysis of that particular outcome 
(although such studies were able to contribute full data 
for analyses of cross-sectional correlates of adiposity 
measures). Participants contributed only ﬁ rst non-fatal 
outcome or death recorded at age 40 years or older 
(ie, deaths preceded by non-fatal coronary heart disease 
or stroke were not included). For the four contributing 
individually matched nested case-control studies within 
prospective cohorts, odds ratios were calculated with 
conditional logistic regression models.
To characterise shapes of associations, study-speciﬁ c 
HRs calculated within overall quantiles of baseline 
adiposity values were pooled on a log scale by multivariate 
random-eﬀ ects meta-analysis and plotted against mean 
values of the relevant adiposity measure within each 
quantile. We estimated 95% CIs from the variances that 
correspond to the amount of information underlying each 
group (including the reference group).21 In the ﬁ gures 
presented, sizes of data markers are proportional to the 
inverse of the variance of the log HRs. Since associations 
were nearly log-linear (except at low values of BMI), we 
calculated HRs associated with 1 SD higher baseline value: 
4·56 kg/m² higher BMI, 12·6 cm higher waist 
circumference, and 0·083 higher waist-to-hip ratio. We 
also calculated HRs with clinically deﬁ ned categories of 
BMI and waist circumference in combination. We 
investigated eﬀ ect-modiﬁ cation with formal tests of 
interaction, and calculated p values for interaction with 
continuous variables, when appropriate. Diversity between 
studies was investigated by grouping studies with recorded 
characteristics and meta-regression. HRs were initially 
adjusted for age, sex, and smoking status only. To explore 
potential biological pathways underlying associations, 
HRs were further adjusted for systolic blood pressure, 
history of diabetes, and total and HDL cholesterol. Extent 
of heterogeneity was indicated by the I² statistic.22 
Regression dilution ratios were obtained by regression of 
serial measurements of the relevant characteristic on 
baseline values. For cardiovascular disease risk prediction 
models, a single Cox model, stratiﬁ ed by study and sex, 
was derived with baseline values of risk factors. Resulting 
predictions were assessed by use of measures of 
discrimination for censored time-to-event data (Harrell’s 
C-index),23 and net reclassiﬁ cation improvement and 
integrated discrimination improve ment was calculated by 
use of four standard 10-year risk categories (<5%, 5% to 
<10%, 10% to <20%, and ≥20%).24 The C-index and its 
changes were calculated in two stages, ﬁ rst with esti-
mation within each study and then pooled with meta-
analysis techniques. Analyses were done with Stata 
(version 11.0), and two-sided p values and 95% CIs 
are presented.
Role of the funding source
The sponsor of the study did not participate in the study 
design, data collection, data analysis, data interpretation, 
or writing of the report. DW and JD had full access to all 
data in the study and had ﬁ nal responsibility to submit 
the report for publication.
Results
Individual records were available for 221 934 participants 
who had no known history of cardiovascular disease 
(ie, myocardial infarction, angina, or stroke, as ascertained 
in each study) at the baseline examination. 155 938 (70%) 
of these participants also had data on smoking status, 
systolic blood pressure, history of diabetes, and total and 
HDL cholesterol. Mean age of participants at baseline was 
58 years (SD 9), 124 189 (56%) were women, and 
129 326 (58%) were in Europe, 73 707 (33%) were in 
North America, 9204 (4%) were in Australia, and 9697 (4%) 
were in Japan (webappendix pp 3–7).
Adiposity measures had broadly similar distri bu-
tions across studies and were approximately linearly 
Adjusted for age, sex, and 
smoking status
Adjusted for age, sex, smoking 
status, and intermediate risk 
factors*
HR (95% CI) I² (95% CI) HR (95% CI) I² (95% CI)
Coronary heart disease (39 studies, 143 710 participants, 5259 cases)
BMI 1·29 (1·22–1·37) 65% (52–75) 1·11 (1·05–1·17) 45% (20–62)
Waist circumference 1·32 (1·24–1·40) 64% (50–75) 1·12 (1·06–1·19) 49% (25–65)
Waist-to-hip ratio 1·30 (1·22–1·38) 65% (51–75) 1·14 (1·09–1·18) 14% (0–42)
Ischaemic stroke (21 studies, 85 169 participants, 2431 cases)
BMI 1·20 (1·12–1·28) 39% (0–64) 1·06 (0·99–1·13) 26% (0–57)
Waist circumference 1·25 (1·18–1·33) 21% (0–54) 1·11 (1·05–1·17) 9% (0–43)
Waist-to-hip ratio 1·25 (1·18–1·32) 21% (0–53) 1·14 (1·09–1·20) 0% (0–47)
Cardiovascular disease (39 studies, 144 795 participants, 8347 cases)
BMI 1·23 (1·17–1·29) 72% (61–79) 1·07 (1·03–1·11) 47% (23–64)
Waist circumference 1·27 (1·20–1·33) 69% (57–78) 1·10 (1·05–1·14) 49% (26–65)
Waist-to-hip ratio 1·25 (1·19–1·31) 67% (54–76) 1·12 (1·08–1·15) 8% (0–38)
HRs are presented per 4·56 kg/m² higher BMI, 12·6 cm higher waist circumference, and 0·083 higher waist-to-hip ratio 
(ie, 1 SD higher baseline values). HRs were adjusted as shown, and stratiﬁ ed, where appropriate, by sex. Analyses were 
restricted to participants with BMI of 20 kg/m² or higher and complete information on age, sex, smoking status, and 
intermediate risk factors. HR=hazard ratio. BMI=body-mass index. *Intermediate risk factors were systolic blood 
pressure, history of diabetes, and total and HDL cholesterol. 
Table 1: Associations of baseline values of BMI, waist circumference, and waist-to-hip ratio with risk of 
coronary heart disease, ischaemic stroke, and cardiovascular disease, adjusted for baseline values of 
confounders and intermediate risk factors
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assoc i ated with one another across the range of values 
(webappendix p 13). Correlation coeﬃ  cients adjusted 
for age and sex were 0·85 (95% CI 0·84–0·86) bet ween 
BMI and waist circumference, 0·43 (0·40–0·45) 
between BMI and waist-to-hip ratio, and 0·70 (0·68–0·72) 
bet ween waist circumference and waist-to-hip ratio. 
Mean adiposity values generally increased with the age 
of participants until about 55–75 years, then ﬂ attened or 
A      Coronary heart disease B      Ischaemic stroke
BMI
Age at survey (years)
40–59
60–69
≥70
Sex
Female
Male
Number
of cases
2644
1999
3049
3070
4680
HR (95% CI)
1·41 (1·30–1·53)
1·23 (1·15–1·31)
1·12 (1·05–1·19)
1·24 (1·14–1·35)
1·26 (1·18–1·34)
Interaction 
p value
0·006
0·643
Number
of cases
669
899
1082
1649
1012
HR (95% CI)
1·34 (1·21–1·48)
1·22 (1·13–1·31)
1·08 (0·99–1·18)
1·20 (1·05–1·37)
1·33 (1·21–1·46)
Interaction 
p value
0·051
0·030
Waist circumference
Age at survey (years)
40–59
60–69
≥70
Sex
Female
Male
BMI (kg/m2)
Bottom third
Middle third
Top third
2644
1999
3049
3070
4680
2127
2602
3021
1·50 (1·37–1·63)
1·28 (1·20–1·37)
1·13 (1·06–1·21)
1·31 (1·21–1·43)
1·24 (1·17–1·32)
1·24 (1·12–1·38)
1·26 (1·17–1·37)
1·27 (1·18–1·37)
<0·0001
0·056
0·965
<0·0001
0·092
0·995
0·0001
0·754
0·967
669
899
1082
1649
1012
734
868
1059
1·45 (1·30–1·60)
1·29 (1·20–1·40)
1·10 (1·03–1·18)
1·27 (1·12–1·43)
1·32 (1·22–1·42)
1·29 (1·12–1·47)
1·23 (1·09–1·40)
1·21 (1·10–1·32)
0·001
0·429
0·136
Waist-to-hip ratio
Age at survey (years)
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Female
Male
BMI (kg/m2)
Bottom third
Middle third
Top third
2644
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4680
2127
2602
3021
1·43 (1·34–1·53)
1·27 (1·19–1·36)
1·14 (1·06–1·21)
1·30 (1·20–1·41)
1·24 (1·17–1·31)
1·24 (1·15–1·33)
1·24 (1·18–1·31)
1·23 (1·17-1·30)
669
899
1082
1649
1012
734
868
1059
1·39 (1·28–1·50)
1·27 (1·18–1·37)
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Figure 2: HRs for coronary heart disease (A) and ischaemic stroke (B) per 1 SD higher baseline values of BMI, waist circumference, and waist-to-hip ratio, 
according to age, sex, and BMI at baseline
Analyses for coronary heart disease were based on up to 203 338 participants from 51 studies, and analyses for ischaemic stroke were based on up to 
122 914 participants from 25 studies. HRs are presented per 4·56 kg/m² higher BMI, 12·6 cm higher waist circumference, and 0·083 higher waist-to-hip ratio 
(ie, 1 SD higher baseline values). Study-speciﬁ c HRs were adjusted for age at baseline and smoking status, and stratiﬁ ed, where appropriate, by sex. Analyses were 
restricted to participants with BMI of 20 kg/m² or higher. X-axes are shown on a log scale. p values for interaction were calculated by use of continuous values of 
variables, when appropriate.  HRs for coronary heart disease, initially adjusted for age, sex, and smoking status, and then additionally adjusted for BMI, were 1·31 
(1·24–1·37) and 1·23 (1·15–1·32), respectively, with waist circumference, and 1·29 (1·23–1·35) and 1·21 (1·16–1·26), respectively, with waist-to-hip ratio. HRs for 
ischaemic stroke, initially adjusted for age, sex, and smoking status, and then additionally adjusted for BMI, were 1·26 (1·19–1·33) and 1·26 (1·16–1·36), 
respectively, with waist circumference, and 1·25 (1·19–1·32) and 1·18 (1·13–1·24), respectively, with waist-to-hip ratio. BMI=body-mass index. HR=hazard ratio.
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declined in participants older than 75 years (web-
appendix p 13). Adiposity measures were higher in 
people with a history of diabetes, were positively 
associated with non-HDL cholesterol, apolipoprotein B, 
triglyceride, ﬁ brinogen, C-reactive protein, and systolic 
blood pressure, and were inversely associated with HDL 
cholesterol and apolipoprotein AI (webappendix pp 8–9 
and 14–15). Systolic blood pressure, non-HDL cholesterol, 
HDL cholesterol, triglyceride, and C-reactive protein had 
similar associations with waist circumference or waist-
to-hip ratio across BMI values (webappendix p 16). 
People with a history of diabetes had higher mean waist 
circumference and waist-to-hip ratio than did people 
without diabetes across the range of BMI values 
(webappendix p 17). Serial adiposity assess ments done 
in up to 63 821 people (mean interval 5·7 years [SD 3·9]) 
were used to calculate regression dilution ratios adjusted 
for age and sex: 0·95 (95% CI 0·93–0·97) for BMI, 0·86 
(0·83–0·89) for waist circum ference, 0·88 (0·85–0·91) 
for hip circum ference, 0·63 (0·57–0·70) for waist-to-hip 
ratio, 0·63 (0·59–0·67) for non-HDL cholesterol, 
and 0·57 (0·52–0·61) for systolic blood pressure. On the 
basis of these regression dilution ratios, reproducibility 
of BMI was higher than that for waist circumference or 
Figure 3: HRs for coronary heart disease across thirds of waist circumference (A) and waist-to-hip ratio (B) by baseline values of BMI
Analyses were based on 203 338 participants (7750 cases) from 51 studies. Analyses were restricted to participants with BMI of 20 kg/m² or higher. Regression 
analyses were adjusted for age at baseline and smoking status, and stratiﬁ ed, where appropriate, by sex. Adjusted study-speciﬁ c log HRs were combined by 
multivariate random-eﬀ ects meta-analysis. Y-axes are shown on a log scale. Reference groups are the lowest third of waist circumference or waist-to-hip ratio in the 
bottom third of BMI. Results were similar for the full BMI range. BMI=body-mass index. HR=hazard ratio.
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waist-to-hip ratio. Between-study heterogeneity for the 
reproduci bility in BMI and waist circumference was 
modest, whereas the corresponding heterogeneity 
for waist-to-hip ratio was substantial (I²=99%; web-
appendix p 18).
During 1·87 million person-years at risk (median 
5·7 years to ﬁ rst outcome, IQR 3·0–9·0), we recorded 
14 297 ﬁ rst-ever outcomes: 8290 coronary heart disease 
outcomes (4982 non-fatal myocardial infarctions and 
3308 coronary heart disease deaths), 2906 incident 
ischaemic stroke outcomes (2763 non-fatal and 143 fatal 
outcomes), 596 haemorrhagic stroke outcomes, 
2070 unclassiﬁ ed stroke outcomes, and 435 other 
cerebrovascular outcomes (webappendix pp 3–4). In 
analyses adjusted for age, sex, and smoking status only, 
we recorded nearly log-linear associations of BMI, waist 
circumference, and waist-to-hip ratio with risk of 
coronary heart disease and ischaemic stroke, except at 
low BMI values (ﬁ gure 1). Associations with coronary 
heart disease risk were similar when clinically deﬁ ned 
categories of BMI and waist circumference were 
combined (webappendix p 19).
To account for non-linear associations at low BMI 
values, further analyses excluded 9355 participants (4%) 
with BMI of less than 20 kg/m². After adjustment for 
age, sex, and smoking status, HRs for coronary heart 
disease and ischaemic stroke were broadly similar for 
BMI, waist circumference, and waist-to-hip ratio (table 1). 
After further adjustment for systolic blood pressure, 
history of diabetes, and total and HDL cholesterol, these 
HRs reduced substantially. HRs reduced even more after 
additional adjustment for C-reactive protein or ﬁ brinogen 
(webappendix p 10). The excess risk of cardiovascular 
disease associated with BMI, waist circumference, and 
waist-to-hip ratio was three-to-four times stronger at age 
of 40–59 years than at older than 70 years, but HRs were 
similar in men and women (ﬁ gure 2, webappendix p 20). 
HRs for waist circumference and waist-to-hip ratio were 
generally similar at diﬀ erent BMI values (ﬁ gures 2 and 3) 
and triglyceride values (webappendix p 21), and HRs 
were slightly reduced after adjustment for BMI (ﬁ gure 2). 
HRs were possibly higher at below-average systolic blood 
pressure, but otherwise did not vary substantially by 
clinical and demographic characteristics recorded 
Figure 4: Changes in C-index for cardiovascular disease risk prediction from addition of adiposity measures or conventional risk factors to a model containing 
age and sex only
Analyses were based on 144 795 participants (8347 cardiovascular events) in 39 studies. Analyses were restricted to participants with BMI of 20 kg/m² or higher. 
BMI=body-mass index. *Reference C-index was 0·6741 (95% CI 0·6685 to 0·6798) for the model including age and stratiﬁ ed by sex. †p=0·0001 for change in C-index 
after addition of waist circumference into the model with age, sex, and BMI. ‡p<0·0001 for change in C-index after addition of waist-to-hip ratio into the model with 
age, sex, and BMI. §Smoking status, systolic blood pressure, and history of diabetes. ¶Smoking status, systolic blood pressure, history of diabetes, and total and HDL 
cholesterol.
Model including age and sex*
Plus BMI only
Plus waist circumference only
Plus waist-to-hip ratio only
Plus BMI and waist circumference only
Plus BMI and waist-to-hip ratio only
Plus non-lipid variables only§
Plus Framingham variables only¶
Reference
0·0051 (0·0031 to 0·0072)
0·0077 (0·0053 to 0·0100)
0·0102 (0·0080 to 0·0125)
0·0077 (0·0054 to 0·0101)†
0·0108 (0·0083 to 0·0134)‡
0·0497 (0·0455 to 0·0538)
0·0584 (0·0539 to 0·0628)
C-index change (95% CI)
0 0·01 0·02 0·03 0·04 0·05 0·06
Figure 5: Changes in C-index for cardiovascular disease risk prediction from addition of adiposity measures or lipid markers to a non-lipid-based model
Analyses were based on 144 795 participants (8347 cardiovascular events) in 39 studies. Analyses were restricted to participants with BMI of 20 kg/m² or higher. 
BMI=body-mass index. *Reference C-index was 0·7238 (95% CI 0·7186 to 0·7291) for the model including age, smoking status, systolic blood pressure, and history of 
diabetes, and stratiﬁ ed by sex. †p=0·175 for change in C-index after addition of waist circumference into the reference model plus BMI. ‡p<0·0001 for change in 
C-index after addition of waist-to-hip ratio into the reference model plus BMI. 
Non-lipid-based model*
Plus BMI only
Plus waist circumference only
Plus waist-to-hip ratio only
Plus BMI and waist circumference only
Plus BMI and waist-to-hip ratio only
Plus total cholesterol only
Plus HDL cholesterol only
Plus both total and HDL cholesterol only
Reference
0·0006 (–0·0002 to 0·0013)
0·0010 (0·0001 to 0·0019)
0·0023 (0·0013 to 0·0033)
0·0010 (0·0000 to 0·0020)†
0·0022 (0·0011 to 0·0033)‡
0·0030 (0·0018 to 0·0041)
0·0051 (0·0037 to 0·0066)
0·0087 (0·0068 to 0·0106)
C-index change (95% CI)
0 0·002 0·004 0·006 0·008 0·010 0·012
Articles
www.thelancet.com   Vol 377   March 26, 2011 1091
(web appendix p 22). Hetero geneity in HRs for BMI, 
waist circumference, and waist-to-hip ratio (table 1) was 
only partly explained by the characteristics recorded 
(webappendix p 22). HRs did not appreciably alter after 
omission of the ﬁ rst 5 or 10 years of follow-up, but 
HRs decreased somewhat after correction for long-
term average (usual) values of systolic blood pressure, 
history of diabetes, and total and HDL cholesterol (data 
not shown).
HRs for BMI, waist circumference, and waist-to-hip 
ratio recorded in the full study population were 
qualitatively similar to those in analyses that excluded 
subgroups of participants or studies: current smokers 
(data not shown); participants who were not of European 
descent (data not shown); the 29 905 participants who 
had only self-reported adiposity measures (data not 
shown); the few studies with the most discrepant ﬁ ndings 
(webappendix p 23); or the 21 139 participants known to 
be receiving lipid-lowering, blood-pressure-lowering, or 
other cardiovascular drugs at baseline (data not shown). 
HRs were also broadly similar in ﬁ xed-eﬀ ect models to 
those in random-eﬀ ects models (webappendix p 23), and 
after additional adjustment for cigarette pack-years (in 
addition to smoking status), alcohol consumption, or 
measures of socioeconomic status (data not shown). We 
recorded no evidence of bias due to small studies 
(webappendix p 24).
When information on BMI, waist circumference, or 
waist-to-hip ratio at baseline was added to a risk 
prediction model with age and sex only, the incremental 
gain in predictive ability was modest (ﬁ gure 4). When 
information on adiposity measures was added to a risk 
prediction model without lipid information but 
containing information on other Framingham risk 
factors (age, sex, smoking status, systolic blood 
pressure, history of diabetes, and HDL and total 
cholesterol), the incremental gain in predictive value 
provided by a combination of BMI and waist-to-hip 
ratio was about a quarter of the predictive gain provided 
by total and HDL cholesterol (ﬁ gure 5). When 
information on lipids and other conventional risk 
factors was available, additional information on BMI, 
waist circumference, or waist-to-hip ratio, either singly 
or in combination, did not appreciably change 
cardiovascular disease risk discrimination, according to 
C-index changes, nor improve reclassiﬁ cation of 
participants into predicted 10-year risk categories 
(table 2).
To assess any incremental gain in predictive ability 
provided by adiposity measures, irrespective of the 
sequence of their addition to a risk model, we assessed 
the eﬀ ect of omission of one risk factor at a time from a 
full model. Omission of BMI and waist circumference 
had nearly zero eﬀ ect, and omission of waist-to-hip ratio 
 BMI Waist circumference Waist-to-hip ratio BMI and waist 
circumference
BMI and 
waist-to-hip ratio
Discrimination (39 studies, 144 795 participants, 8347 cases)
C-index change (95% CI)* –0·0001 
(–0·0005 to 0·0002)
–0·0001 
(–0·0006 to 0·0005)
0·0008 
(0·0001 to 0·0014)
0·0000 
(–0·0005 to 0·0006)
0·0006
(0·0000 to 0·0013)
p value† 0·430 0·816 0·027 0·933 0·068
p value‡ Reference 0·627 0·006 0·454 0·009
Reclassiﬁ cation (20 studies, 43 944 non-cases, 4777 cases)
Participants who developed cardiovascular disease at 10 years    
Appropriately reclassiﬁ ed 68 (1·42%) 111 (2·32%) 132 (2·76%) 106 (2·22%) 141 (2·95%)
Inappropriately reclassiﬁ ed 73 (1·53%) 110 (2·30%) 136 (2·85%) 116 (2·43%) 142 (2·97%)
No change 4636 (97·05%) 4556 (95·37%) 4509 (94·39%) 4555 (95·35%) 4494 (94·08%)
Participants who were event free at 10 years  
Appropriately reclassiﬁ ed 507 (1·15%) 806 (1·83%) 1091 (2·48%) 856 (1·95%) 1111 (2·53%)
Inappropriately reclassiﬁ ed 545 (1·24%) 839 (1·91%) 1078 (2·45%) 847 (1·93%) 1116 (2·54%)
No change 42 892 (97·61%) 42 299 (96·26%) 41  775 (95·06%) 42 241 (96·12%) 41 717 (94·93%)
Net reclassiﬁ cation improvement (95% CI) –0·19% 
(–0·70 to 0·32)
–0·05% 
(–0·69 to 0·58)
–0·05% 
(–0·76 to 0·65)
–0·19%
(–0·83 to 0·45)
–0·03%
(–0·75 to 0·69)
p value 0·461 0·867 0·880 0·562 0·930
Integrated discrimination improvement (95% CI) 0·0001 
(–0·0002 to 0·0003)
0·0004 
(0·0000 to 0·0007)
0·0010 
(0·0004 to 0·0015)
0·0005 
(0·0001 to 0·0008)
0·0009 
(0·0004 to 0·0015)
p value 0·654 0·043 0·0003 0·016 0·001
Framingham risk score covariates include age, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol, and model was stratiﬁ ed by sex. Analyses are restricted to cohort studies 
and participants with BMI of 20 kg/m2 or higher. Cohort studies recording both fatal and non-fatal cardiovascular outcomes and more than 10 years of follow-up contributed to reclassiﬁ cation analyses. 
BMI=body-mass index. *Reference C-index was 0·7325 (95% CI 0·7274 to 0·7376) for the model including Framingham risk score covariates. †p value is for changes in C-index as compared with a model including 
Framingham risk score covariates. ‡p value is for changes in C-index as compared with addition of BMI alone.
Table 2: Reclassiﬁ cation of 10-year predicted risk and changes in risk discrimination for cardiovascular disease after addition of adiposity measures to a model including Framingham risk 
score covariates
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had a small eﬀ ect (ﬁ gure 6). This result applied in 
analyses that either included or omitted people with 
history of diabetes at baseline (webappendix p 25), 
and for a wide range of other circumstances (web-
appendix p 26). Qualitatively similar results to those 
noted above were recorded in analyses assessing 
integrated discrimination improvement (table 2, 
webappendix p 11). We could not assess risk prediction 
at diﬀ erent ages because age distributions diﬀ ered 
substantially between studies.
Discussion
The results from our analysis of individual data from 
221 934 people without initial cardiovascular disease 
have shown that BMI, waist circumference, or waist-to-
hip ratio, assessed singly or in combination, do not 
importantly improve prediction of cardiovascular 
disease risk when additional information is available on 
blood pressure, history of diabetes, and cholesterol 
measures (panel). This ﬁ nding applies to a wide range 
of circumstances and clinically relevant subgroups.
The main ﬁ nding of this study does not, of course, 
diminish the importance of adiposity as a major 
modiﬁ able determinant of cardiovascular disease. 
Rather, because excess adiposity is a major determinant 
of the intermediate risk factors noted above,3 our 
ﬁ ndings underscore the importance of controlling 
adiposity to help prevent cardiovascular disease. These 
data also suggest the relevance of controlling 
intermediate risk factors to combat the detrimental 
vascular eﬀ ects of overweight and obesity.25 However, 
the ﬁ ndings of our study indicate that for population-
wide assessment of cardiovascular disease risk, when 
additional information is available on factors used in 
standard risk scores, simple adiposity measures provide 
little or no additional information on cardiovascular 
risk. Even so, other reasons could support inclusion of 
adiposity measures in risk assessment, such as 
promotion of behaviour change26 or improvement of 
risk communication. Findings of previous smaller 
studies (and WHO guidelines) have suggested that for 
situations in which no information is available on lipids 
for cardiovascular disease risk prediction (such as in 
resource-limited settings), assessment of simple 
adiposity measures can be used instead, with only a 
modest loss of predictive ability.27,28 However, data from 
Figure 6: Changes in C-index for cardiovascular disease risk prediction from omission of individual risk factors from a full model containing Framingham risk 
score covariates plus BMI, waist circumference, or waist-to-hip ratio
Analyses were based on 144 795 participants (8347 cardiovascular events) in 39 studies. Analyses were restricted to participants with BMI of 20 kg/m² or higher. 
BMI=body-mass index. *Framingham risk score covariates include age, smoking status, systolic blood pressure, history of diabetes, and total and HDL cholesterol, and 
model was stratiﬁ ed by sex. †Reference C-index of 0·7324 (95% CI 0·7272 to 0·7375). ‡Reference C-index of 0·7324 (95% CI 0·7273 to 0·7376). §Reference C-index 
of 0·7333 (95% CI 0·7281 to 0·7384).
BMI
Model including Framingham risk score covariates* plus BMI†
Smoking status
Systolic blood pressure
History of diabetes
Total cholesterol
HDL cholesterol
BMI
Waist circumference
Model including Framingham risk score covariates* plus waist circumference‡
Smoking status
Systolic blood pressure
History of diabetes
Total cholesterol
HDL cholesterol
Waist circumference
Waist-to-hip ratio
Model including Framingham risk score covariates* plus waist-to-hip ratio§
Smoking status
Systolic blood pressure
History of diabetes
Total cholesterol
HDL cholesterol
Waist-to-hip ratio
Reference
–0·0110 (–0·0130 to –0·0090)
–0·0147 (–0·0169 to –0·0125)
–0·0078 (–0·0094 to –0·0062)
–0·0035 (–0·0047 to –0·0023)
–0·0051 (–0·0065 to –0·0037)
0·0001 (–0·0002 to 0·0005)
Reference
–0·0111 (–0·0130 to –0·0091)
–0·0145 (–0·0167 to –0·0123)
–0·0075 (–0·0091 to –0·0060)
–0·0036 (–0·0048 to –0·0024)
–0·0048 (–0·0061 to –0·0034)
0·0001 (–0·0005 to 0·0006)
Reference
–0·0107 (–0·0126 to –0·0088)
–0·0143 (–0·0166 to –0·0121)
–0·0073 (–0·0089 to –0·0058)
–0·0033 (–0·0045 to –0·0022)
–0·0046 (–0·0059 to –0·0033)
–0·0008 (–0·0014 to –0·0001)
C-index change (95% CI)
–0·020 –0·0150 –0·010 –0·005 0 0·005
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our study indicate that a combination of BMI and waist-
to-hip ratio provides only about a quarter of the extra 
predictive information provided by total and HDL 
cholesterol. The ﬁ ndings of our study emphasise, 
therefore, the desirability of supporting the development 
of lipid assessment in resource-poor settings.
Our ﬁ ndings reliably refute previous recommendations 
to adopt baseline waist-to-hip ratio instead of BMI as the 
principal clinical measure of adiposity.5 Contrary to a 
report from INTERHEART (a large retrospective case-
control study of acute myocardial infarction) that waist-
to-hip ratio is three times more strongly related to 
myocardial infarction than is BMI,5 we have shown that 
BMI, waist circumference, and waist-to-hip ratio each 
have a similar strength of association with cardiovascular 
disease risk. Indeed, the odds ratio for myocardial 
infarction was only 1·12 per 5 kg/m² higher baseline 
BMI in INTERHEART,5 whereas the HR for coronary 
heart disease per 5 kg/m² higher baseline BMI was 1·32 
in our study. This discrepancy might be due to the 
greater susceptibility of retrospective studies of acute 
myocardial infarction to some biases (eg, selection 
biases, reverse causality) than are long-term prospective 
studies of people without a history of cardiovascular 
disease, as in our analysis. Furthermore, results from 
our study indicate that the long-term reproducibility of 
BMI is superior to that of waist-to-hip ratio (or waist 
circumference).
Findings from our study could provide insight into 
cardiovascular disease mechanisms. Measures of 
abdominal adiposity, such as waist circumference and 
waist-to-hip ratio (especially in combination with high 
triglyceride concentration29), might be better indicators 
of visceral fat accumulation and an adverse metabolic 
proﬁ le than is raised BMI alone, since BMI is a measure 
of general adiposity.30,31 Yet, our results indicate that 
BMI, waist circumference, and waist-to-hip ratio each 
have a similar strength of association with cardiovascular 
disease risk, including similar associations with 
coronary heart disease and ischaemic stroke. The 
similarity of eﬀ ect of adiposity on coronary heart disease 
and ischaemic stroke contrasts with results previously 
reported for proatherogenic lipids (which are more 
strongly associated with coronary heart disease than 
ischaemic stroke32) and systolic blood pressure (which 
is more strongly related to ischaemic stroke than 
coronary heart disease33). Our data, therefore, 
underscore the potential importance of reduction of 
adiposity for both coronary heart disease and ischaemic 
stroke. We did not record any modiﬁ cation of the eﬀ ect 
of abdominal adiposity on cardiovascular disease risk 
by BMI. By contrast, age was a strong eﬀ ect-modiﬁ er, 
with about three-to-four times higher excess risk in 
early middle age than in individuals older than 
70 years.34
Our study importantly extends previous analyses of 
prospective studies. By contrast with analyses from the 
Prospective Studies Collaboration (PSC)6 and the 
National Cancer Institute Cohort Consortium (NCICC),7 
and a study of BMI in 1·1 millian Asians,35 which lacked 
information on waist circumference and waist-to-hip 
ratio, our study had concomitant data for each participant 
on BMI, waist circumference, and waist-to-hip ratio. By 
contrast with analyses from NCICC and the European 
Prospective Investigation into Cancer8 (EPIC), which 
lacked information on lipids, our study had concomitant 
information on lipids, blood pressure, and other 
conventional risk factors. The PSC, NCICC, and EPIC 
analyses all lacked non-fatal cardiovascular disease 
outcomes, whereas our study comprised 14 297 fatal or 
ﬁ rst-onset non-fatal outcomes of cardiovascular disease 
recorded during 1·87 million person-years at risk. Our 
study has twice as many cardiovascular disease outcomes 
than in the NCICC analysis and four times more than in 
the EPIC analysis, with less than 10% of data in our 
study overlapping with these previously published 
analyses. A unique feature of our study is inclusion of 
long-term serial assessments of BMI, waist 
circumference, and waist-to-hip ratio for up to 
63 821 people. The generalisability of our ﬁ ndings, at 
least to populations in developed countries, is supported 
by broadly consistent results across 58 studies in 
17 countries. Because 90% of the participants in this 
study were of European descent, additional studies are 
needed in people of non-European descent.36–38 
Nevertheless, our ﬁ nding that adiposity measures, 
Panel: Research in context
Systematic review
Findings of a previous systematic review of 27 guideline statements showed substantial 
variation in recommendations about the value of inclusion of clinical measures of adiposity 
in risk scores for the primary prevention of cardiovascular disease in developed countries.1 
Recommendations range from omission of adiposity measures, to inclusion of such 
measures as additional screening tests, to formal inclusion of such measures as risk factors 
in prediction models. This lack of consensus is an indication, in part, of uncertainty in the 
epidemiological evidence about the predictive value of adiposity measures in the context of 
information on other conventional risk factors. 5–12
In our investigation, individual participant data (ie, primary records) were collated and 
harmonised from all available relevant long-term prospective studies of cardiovascular 
disease, and analyses were restricted to individuals in these studies without a history of 
cardiovascular disease at the initial examination. These studies were identiﬁ ed by 
computerised searches of electronic databases (eg, PubMed), inspection of reference lists of 
relevant studies, manual searches, and discussion with investigators. The main analyses 
included people with concomitant information on body-mass index, waist circumference, 
waist-to-hip ratio, and several other conventional risk factors (ie, age, sex, blood pressure, 
history of diabetes, and total and HDL cholesterol).
Interpretation
The results from this study show that, whether assessed singly or in combination, 
body-mass index, waist circumference, and waist-to-hip ratio do not importantly 
improve prediction of ﬁ rst-onset cardiovascular disease when additional information 
exists on blood pressure, history of diabetes, and cholesterol measures.
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whether assessed singly or in combination, do not 
importantly improve prediction of cardiovascular risk 
when additional information is available on blood 
pressure, history of diabetes, and lipids, should help to 
clarify divergent recommendations in cardiovascular 
disease guidelines about clinical measures of adiposity 
in assessment of risk.
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